News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

First Naviscan, Inc. PET Scanner Installed in Turkey


1/31/2012 8:38:18 AM

SAN DIEGO, CA--(Marketwire - January 31, 2012) -

A Naviscan PET scanner performing Positron Emission Mammography (PEM) has been installed at the prestigious MEDICA Medical Center in Istanbul, Turkey. Capitalizing on Naviscan's distribution in 13 European countries, this marks the first installation of a backlog of orders in the European market.

"After PET/CT that has capability of N and M staging capability on breast cancer, PEM is a powerful tool to define T staging with high sensitivity and specificity," said Dr. Okan Falay, Nuclear Medicine Chief at MEDICA Medical Center. "In recent years due to increased breast-conserving surgery, neoadjuvant treatment has become a therapy choice because of locally advanced cancer and possibility of locoregional recurrence. PEM can give information much earlier than MRI and mammography as a routine diagnostic method about therapy monitoring and recurrence."

PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term "specificity." Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only FDA-cleared, CE-certified 3D Molecular Breast Imaging (MBI) device on the market with biopsy-guidance.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and is globally distributed in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.


Contact Information
Guillaume Bailliard
Executive Vice President
Naviscan, Inc.
Tel: +1.858.332.0941
Email Contact

Joleen Schultz
Naviscan Marketing Communications
321 Medical Launch
Tel: +1.858.455.5500
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES